In Brief: Respiratory Depression with Gabapentinoids
Date: June 1, 2020
Issue #:
1599Summary:
The FDA has required new warnings in the labels of
gabapentin (Neurontin, and others) and pregabalin (Lyrica,Lyrica CR, and generics) about the risk of life-threatening or
fatal respiratory depression in patients with respiratory risk
factors. Respiratory risk factors include chronic obstructive
pulmonary disease (COPD) and concurrent use of opioids
or other CNS depressants. Elderly patients are also at
increased risk.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: COPD Drug Safety Gabapentin Lyrica Neurontin Opioids Pregabalin Source Type: research
More News: Brain | Chronic Obstructive Pulmonary | Depression | Drugs & Pharmacology | Gabapentin | Lyrica | Neurology | Neurontin | Respiratory Medicine | Warnings